The following is a summary of the CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript:
Financial Performance:
CareDx reported Q3 revenue of $82.9 million, a 23% year-over-year growth.
Adjusted EBITDA was $6.9 million, substantially above the EBITDA-neutral guide.
Generated $12.5 million in cash from operations and ended with $241 million in cash and cash equivalents.
Business Progress:
Delivered approximately 44,600 tests, up 16% from the previous year.
Added 15 of a planned 30 sales and marketing team members to promote transplant solutions.
Collaboration with the University of California Health System to implement MedActionPlan.
Opportunities:
Coverage from Medicare and Medicaid Services reaffirmed for solid organ transplant monitoring.
Expanded commercial covered lives by four million in Q3. Highmark Blue Cross Blue Shield recently expanded coverage for AlloSure Kidney and HeartCare.
Risks:
No explicit risks detected.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
